A new preliminary study has suggested that people with type 2 diabetes who use GLP-1 medications (such as Ozempic and Trulicity) may have a modestly lower likelihood of developing epilepsy compared to those taking other glucose-lowering drugs. Specifically, the GLP-1 users were 16% less likely to develop epilepsy. Researchers caution that this finding shows an association, not proof of cause and effect, and emphasize the need for rigorous, long-term randomized clinical trials to confirm the encouraging early signal for brain health.
